Posterior Cervical Fixation Study

Degenerative Disc Disease Clinical Trial

Official title:

A Prospective, Multicenter Study Evaluating the Safety and Performance of Posterior Fixation in Trauma, Reconstructive, and Tumor Surgery of the Occipito-cervico-thoracic Spine

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04770571
• Other study ID #: NUVA.PCF1020
• Status: Enrolling by invitation
• Start date: May 10, 2022
• Est. completion date: December 2025

Study information

• Verified date: February 2024
• Source: NuVasive
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this study is to evaluate the safety and performance of occipito-cervico-thoracic spine surgery using posterior fixation as measured by reported complications, radiographic outcomes, and patients reported outcomes (PROs).This study is being undertaken to identify possible residual risks and to clarify mid-to long-term clinical performance that may affect the benefit/risk ratio of posterior fixation systems.

Description:

This study is a prospective, uncontrolled, multicenter study to evaluate the safety and performance of select occipito-cervico-thoracic posterior fixation systems in patients who undergo posterior fixation fusion surgery. Consecutive patients at a given site who meet eligibility requirements will be asked to consent to participate in the study. These patients will present with traumatic, reconstructive, and/or tumor conditions in the craniocervical, cervical, and/or upper thoracic spine that are amenable to surgical treatment and will be screened prior to study enrollment. Once enrolled in the study, subjects will undergo posterior occipito-cervico-thoracic fixation surgery using one of the NuVasive posterior fixation systems (Vuepoint II OCT or Reline-C) based on the surgeon's standard of care. At least 150 subjects (a minimum of 75 in each implant arm) will be enrolled and will be followed for 24 months after the surgery.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 150
• Est. completion date: December 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients who are =18 years of age at the time of consent

2. Have planned craniocervical, cervical (C1 to C7), and/or upper thoracic (T1-T3) spine surgery using posterior fixation planned for treatment of any of the following

conditions:

1. traumatic spinal fractures and/or traumatic dislocations

2. instability or deformity

3. failed previous fusions (e.g., pseudoarthrosis)

4. tumors involving the cervical spine

5. degenerative disease, including intractable radiculopathy and/or myelopathy, neck and/or arm pain of discogenic origin as confirmed by radiographic studies, and degenerative disease of the facets with instability

3. Using one of the following posterior occipito-cervico-thoracic fixation systems

(NuVasive, Inc, San Diego, CA):

1. Vuepoint II OCT

2. Reline-C

4. Able to undergo surgery based on physical exam, medical history, and surgeon judgment

5. Understands the conditions of enrollment and is willing to sign an informed consent form to participate in the study

Exclusion Criteria:

1. Patient is involved in active litigation relating to the spine (workers' compensation claim is allowed if it is not contested)

2. Use of bone growth stimulators postoperatively

3. Active smoking within 6 weeks of surgery

4. Patient has known sensitivity to materials implanted

5. Systemic or local infection (latent or active) or signs of local inflammation

6. Patient has inadequate bone stock or quality, or a physical or medical condition that would prohibit beneficial surgical outcome based on surgeon judgment

7. Pregnant, or plans to become pregnant

8. Patient is a prisoner

9. Patient is participating in another clinical study that would confound study data

Related Conditions & MeSH terms

• Cervical Disc Disease
• Cervical Fusion
• Cervical Instabilities Spine
• Cervical Myelopathy
• Cervical Radiculopathy
• Cervical Spine Disease
• Craniocervical Injuries
• Degenerative Disc Disease
• Intervertebral Disc Degeneration
• Radiculopathy
• Spinal Cord Diseases
• Spinal Diseases
• Thoracic Injuries
• Thoracic Injury
• Trauma, Nervous System
• Wounds and Injuries

Locations

Country	Name	City	State
United States	Houston Methodist	Houston	Texas
United States	MedStar Health Research Institute	Hyattsville	Maryland
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	NY Spine Institute	New York	New York
United States	UC Irvine Medical Center	Orange	California

Sponsors (1)

Lead Sponsor	Collaborator
NuVasive

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complications of Posterior Fixation System	Rate of complications (i.e., safety) attributable to the use of the associated posterior fixation system.	24 months
Primary	Radiographic Success	The proportion of subjects with apparent radiographic success at: Latest timepoint available for patients undergoing surgery to treat advanced stage tumors; 24 months postoperative for subjects undergoing surgery to treat instabilities, traumatic spinal fractures, failed previous fusions, or degenerative disease	24 months
Secondary	Percentage of subjects meeting minimal clinically important difference (MCID) as compared to baseline for neck/arm pain measured by visual analog scale (VAS).	Neck and arm pain measured using a visual analog scale (VAS) will be assessed to determine the percentage of subjects who meet MCID (2.5 points and 2.5 points respectively) where 0 is "No Pain" and 10 is "Unbearable Pain".	24 months
Secondary	Percentage of subjects meeting minimal clinically important difference (MCID) as compared to baseline for disability measured by the neck disability index.	Disability measured by the neck disability index (NDI) will be assessed to determine the percentage of subjects who meet MCID (7.5 points) where a higher score on the NDI indicates a more severe disability.	24 months
Secondary	Percentage of subjects meeting minimal clinically important difference (MCID) as compared to baseline measured by overall physical and mental health from PROMIS-10.	Overall physical and mental health measured by PROMIS-10 will be assessed to determine the percentage of subjects who meet MCID (5 points). PROMIS-10 scoring uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.	24 months
Secondary	Percentage of subjects meeting substantial clinical benefit (SCB) for neck/arm pain as compared to baseline for neck/arm pain measured by visual analog scale (VAS).	Neck and arm pain measured using a visual analog scale (VAS) will be assessed to determine the percentage of subjects who meet SCB (3.5 points) where 0 is "No Pain" and 10 is "Unbearable Pain".	24 months
Secondary	Percentage of subjects meeting substantial clinical benefit (SCB) as compared to baseline for disability measured by the neck disability index.	Disability measured by the neck disability index (NDI) will be assessed to determine the percentage of subjects who meet SCB (9.5 points) where a higher score on the NDI indicates a more severe disability.	24 months
Secondary	Percentage of subjects meeting substantial clinical benefit (SCB) as compared to baseline measured by overall physical and mental health from PROMIS-10.	Overall physical and mental health measured by PROMIS-10 will be assessed to determine the percentage of subjects who meet SCB (6.8 points). PROMIS-10 scoring uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.	24 months
Secondary	Rate of complications attributable to the use of any additional NuVasive instruments, implants, or technologies	Rate of complications attributable to the use of any additional NuVasive instruments, implants, or technologies.	24 months